A multi-institutional research team led by the Cincinnati Children’s Heart Institute developed an experimental technology that uses genetics-guided biomechanics and patient-derived stem cells to predict what type of inherited heart defect a child will develop.
The researchers report May 19 in the journal Cell the technology would let doctors intervene earlier to help patients manage their conditions and help inform future pharmacologic treatment options. “This technology would make it possible to predict the eventual cardiac phenotype in pediatric patients and help guide their treatment and future monitoring,” said Jeffery Molkentin, PhD, lead author and a researcher in the Division of Molecular Cardiovascular Biology at Cincinnati Children’s and the Howard Hughes Medical Institute.
Learn more about the study at FoxNews Health and MedCity News.
Write a comment
Comments